Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial Evaluating the Safety and Tolerability of Intratumoral Injections of NanoPac® With Standard of Care Therapy in Subjects With Lung Cancer

NCT04314895 is registered in ClinicalTrials.gov with NanOlogy, LLC as lead sponsor.

NCT NCT04314895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04314895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial Evaluating the Safety and Tolerability of Intratumoral Injections of NanoPac® With Standard of Care Therapy in Subjects With Lung Cancer
Lead sponsor
NanOlogy, LLC
Phase
Phase 2
Overall status
Completed
Start date
April 14, 2021
Completion date
September 26, 2023
Enrollment
18 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, lung cancer, nonsmall cell, lung cancer, small cell, neoplasm of lung